NeuroOne's StereoCED Platform Hits Key Milestone in Robotic Drug Delivery
NMTC sits 56% above its 52-week low of $1.423 on light trading volume (0.2× avg).
Summary
NeuroOne successfully completed three large-animal procedures with its next-generation StereoCED platform, demonstrating combined drug delivery and electrophysiological recording—a first in convection-enhanced delivery. The company announced successful robotic-assisted drug delivery using the StereoCED platform in an SEC filing. This milestone supports the planned launch of StereoCED for human investigational clinical studies later this quarter, with related revenue expected in fiscal Q4 2026. The company's cash position remains tight at $2.0M with going concern doubt, making this progress critical for its capital-raising narrative. The ISO 13485 certification from earlier this month and this technical validation strengthen the case for the platform's commercial potential.
At the time of this announcement, NMTC was trading at $2.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.2M. The 52-week trading range was $1.42 to $6.96. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: EQS.